Massachusetts - based biotech start - up Avrobio has raised $ 60 m in a series B funding round col - led by Cormorant Asset Management and Surveyor Capital . Avrobio has developed a gene therapy for Fabry disease , a lysosomal storage disorder which allows fatty acids to build up in the body . Xconomy Boston — Clinical trials last autumn saw patients ' enzyme levels resemble those without the disease , with no side - effects after 18 months of treatment . The latest funding , which followed a $ 30 m series A in 2016 , will be used to begin a phase 2 trial of the gene therapy AVR - 1 .
Massachusetts - based biotech start - up Avrobio has raised $ 60 m in a series B funding round col - led by Cormorant Asset Management and Surveyor Capital . Avrobio has developed a gene therapy for Fabry disease , a lysosomal storage disorder which allows fatty acids to build up in the body . Clinical trials last autumn saw patients ' enzyme levels resemble those without the disease , with no side - effects after 18 months of treatment . The latest funding , which followed a $ 30 m series A in 2016 , will be used to begin a phase 2 trial of the gene therapy AVR - 1 .